Company intelligence / Profile preview
Captor Therapeutics
Basel, Basel-Stadt, Switzerlandcaptortherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company’s two lead assets, CT‑01 and CT‑03, are entering or have entered Phase I clinical trials targeting hepatocellular carcinoma and haematological malignancies, respectively. Both have shown compelling efficacy in animal models. Two additional programs, CT‑02 and CT‑05, are advancing through preclinical studies focused on autoimmune/inflammatory diseases. Clinical data readouts from the first-in-human studies are expected between late 2024–2025. No published human efficacy results as of May 2025.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Targeted Protein Degradation (TPD)Molecular gluesBifunctional degraders
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
Ono Pharmaceutical Co., Ltd. – collaboration in neurodegeneration initiated at the end of 2022
Beyond the preview
Go deeper on Captor Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Captor Therapeutics.